<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639025</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-LUN-PAS01</org_study_id>
    <nct_id>NCT03639025</nct_id>
  </id_info>
  <brief_title>OCS™ Lung TOP Registry For Donor Lungs for Transplantation</brief_title>
  <acronym>TOP</acronym>
  <official_title>The Organ Care System (OCS™) Lung Thoracic Organ Perfusion (TOP) Registry for Donor Lungs for Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm, prospective, multi-center, post-approval U.S. registry
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an all-comers registry that will enroll:

        1. Consented patients who receive OCS™ preserved double lung transplants from either
           standard criteria donors or donors initially deemed unacceptable; and

        2. Consented patients who receive a single lung transplant from OCS™ preserved lung pairs
           from either standard criteria donors or donors initially deemed unacceptable; and

        3. All donor lungs that were perfused on OCS Lung System.

      Enrolled patients will fall into one of the following three possible analysis categories:

        1. TOP SCDL PAS Primary Analysis Population: will be comprised of the first 289
           eligible/PAS consented recipients transplanted with SCDL primary analysis population
           eligible donor lungs preserved on the OCS™ Lung System.

        2. TOP DLIDU Primary Analysis Population: Will be comprised of the first 266 eligible/PAS
           consented recipients transplanted with DLIDU primary analysis population eligible donor
           lungs preserved on the OCS™ Lung System.

        3. All Other Enrolled Patients: will be comprised of all OCS Lung transplanted patients in
           the TOP Registry that do not meet any of the above analysis populations.

      Patient enrollment in the TOP Registry will continue until both the 289 Primary Analysis
      Population for OCS-preserved standard criteria donor lungs and 266 Primary Analysis
      Population for OCS-preserved donor lungs initially deemed unacceptable have been completed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>12-month patient and graft survival post double-lung transplant</measure>
    <time_frame>12 months</time_frame>
    <description>Primary Effectiveness Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Standard Criteria Donor Lungs - Total ischemic time for OCS™-preserved lungs</measure>
    <time_frame>2 hours</time_frame>
    <description>Lung ischemic time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard Criteria Lungs - Incidence of Primary Graft Dysfunction (PGD) grade 3 within the initial 72 hours post-transplantation (T0, T24, T48, and T72 hours)</measure>
    <time_frame>0, 24, 48 and 72 hours</time_frame>
    <description>Primary Graft Dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Lungs Initially Deemed Unacceptable - Incidence of PGD3 at 72 hours post-transplantation</measure>
    <time_frame>72 hours</time_frame>
    <description>Primary Graft Dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Lungs Initially Deemed Unacceptable - Donor Lung Utilization Rate</measure>
    <time_frame>1 hour</time_frame>
    <description>Utilization Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Lungs Initially Deemed Unacceptable - Incidence of PGD3 within the initial 72 hours post-transplantation</measure>
    <time_frame>Within 72 hours post-transplantation</time_frame>
    <description>Primary Graft Dysfunction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Standard Criteria Lungs - Incidence of PGD3 at T72 hours</measure>
    <time_frame>72 hours</time_frame>
    <description>Primary Graft Dysfunction</description>
  </other_outcome>
  <other_outcome>
    <measure>Total ischemia and cross-clamp times for 1st and 2nd transplanted lungs</measure>
    <time_frame>2 hours</time_frame>
    <description>Ischemic and cross-clamp times</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier survival estimated at Month 1, 6, 12, 24, 36, 48 and 60</measure>
    <time_frame>1,6,12,24,36,48,60 months</time_frame>
    <description>Survival evaluation (K-M)</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival incidence at Month 6, 12, 24, 36, 48 and 60</measure>
    <time_frame>6,12,24,36,48,60 months</time_frame>
    <description>Survival incidence (simple proportion)</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier BOS-free survival estimated at Month 12, 24, 36, 48 and 60</measure>
    <time_frame>12,24,36,48,60 months</time_frame>
    <description>BOS free survival (K-M)</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier Freedom from BOS estimated at Month 12, 24, 36, 48 and 60</measure>
    <time_frame>12,24,36,48,60 months</time_frame>
    <description>Freedom from BOS (K-M)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Bronchiolitis Obliterans Syndrome (BOS) at Month 12, 24, 36, 48 and 60</measure>
    <time_frame>12,24,36,48,60 months</time_frame>
    <description>BOS Incidence (simple proportion)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of re-transplantation (graft failure) at Month 12, 24, 36, 48 and 60</measure>
    <time_frame>12,24,36,48,60 months</time_frame>
    <description>Graft failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Kaplan-Meier transplantation-free survival estimated at Month 12, 24, 36, 48 and 60</measure>
    <time_frame>12,24,36,48,60 months</time_frame>
    <description>Graft failure</description>
  </other_outcome>
  <other_outcome>
    <measure>Lung graft-related SAEs through 30 days post-transplant or discharge - Bronchial anastomotic complications; Major pulmonary-related infection</measure>
    <time_frame>30 days or hospital discharge (whichever is longer)</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival incidence at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Survival incidence at initial transplant surgery hospital discharge, if longer than 30 days.</measure>
    <time_frame>30 days or hospital discharge (whichever is longer)</time_frame>
    <description>Safety Endpoint</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">555</enrollment>
  <condition>Lung Transplantation</condition>
  <arm_group>
    <arm_group_label>Standard Donor Lungs Primary Analysis Population</arm_group_label>
    <description>The first 289 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Initially Unacceptable Donor Lung Primary Analysis Pop.</arm_group_label>
    <description>The first 266 eligible/PAS consented recipients transplanted with primary analysis population eligible donor lungs preserved on the OCS™ Lung System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>All Other Enrolled Patients</arm_group_label>
    <description>All OCS Lung transplanted patients that do not meet any of the above analysis populations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Lung System</intervention_name>
    <description>The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:
Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.
Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.
Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant.</description>
    <arm_group_label>All Other Enrolled Patients</arm_group_label>
    <arm_group_label>Initially Unacceptable Donor Lung Primary Analysis Pop.</arm_group_label>
    <arm_group_label>Standard Donor Lungs Primary Analysis Population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All lung transplant recipients whose donor lungs were preserved on the OCS™ Lung System
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        This is an all-comers registry that will enroll all:

          -  Consented patients who receive OCS™ preserved double lung transplants from either
             standard criteria donors or donors initially deemed unacceptable; and

          -  Consented patients who receive a single lung transplant from OCS™ preserved lung pairs
             from either standard criteria donors or donors initially deemed unacceptable; and

          -  All donor lungs that were perfused on OCS Lung System.

        Enrolled patients will fall into one of the following three possible analysis categories:

          -  TOP SCDL PAS Primary Analysis Population: will be comprised of the first 289
             eligible/PAS consented recipients transplanted with SCDL primary analysis population
             eligible donor lungs preserved on the OCS™ Lung System.

          -  TOP DLIDU Primary Analysis Population: Will be comprised of the first 266 eligible/PAS
             consented recipients transplanted with DLIDU primary analysis population eligible
             donor lungs preserved on the OCS™ Lung System.

          -  All Other Enrolled Patients: will be comprised of all OCS Lung transplanted patients
             in the TOP Registry that do not meet any of the above analysis populations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kausar Qidwai</last_name>
    <phone>9785220984</phone>
    <email>kqidwai@transmedics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Seal, RN, BSN</last_name>
      <email>lynda.seal@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael A Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Satou, RN</last_name>
      <phone>310-206-4168</phone>
      <email>nsatou@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Abbas Ardehali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachelle Villanueva</last_name>
      <phone>650-721-6241</phone>
      <email>rvilla@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Anson M Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Chen</last_name>
      <phone>415-353-7995</phone>
      <email>joy.chen@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Jasleen Kukreja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Diaz</last_name>
      <phone>787-236-4332</phone>
      <email>luisd2@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>John Dunning, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tae Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Errol Bush, MD</last_name>
      <email>errol.bush@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Errol Bush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauricio Villavicencio, MD</last_name>
      <phone>617-726-5608</phone>
      <email>MVillavicencio@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mauricio Villavicencio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan Nemeh, MD</last_name>
      <phone>313-916-2600</phone>
      <email>hnemeh1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Hassan Nemeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Lemke</last_name>
      <email>ntlemke@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Huddleston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia McCain</last_name>
      <phone>402-559-3213</phone>
      <email>natalia.mccain@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Aleem Siddique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Mamczur-Madry, RN, BSN, MS</last_name>
      <phone>718-920-3576</phone>
      <email>mmamczur@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Scott Scheinin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Lane, BSN, RN</last_name>
      <email>kathleen.rohrback@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew G Hartwig, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor St. Luke's Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Loor, MD</last_name>
      <phone>832-355-3000</phone>
      <email>gabriel.loor@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed O Gaber, MD</last_name>
      <phone>713-441-5451</phone>
      <email>AOGaber@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Krupnick, MD</last_name>
    </contact>
    <contact_backup>
      <email>ak2yf@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander Krupnick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucien Durham, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Lucien Durham, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>May 31, 2020</last_update_submitted>
  <last_update_submitted_qc>May 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

